Medicine Supply Notification: Oxybutynin (Kentera® ) 3.9mg/24hours transdermal patches
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches.
MSN/2026/004
Tier 2 – Medium impact
Date of issue: 28 January 2026
- Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches are out of stock until late-February 2026.
- Oxybutynin 5mg and 10mg modified-release tablets remain available and can support increased demand.
- Oxybutynin 2.5mg/5ml and 5mg/5ml oral solution sugar free remains available and can support increased demand.
- Oxybutynin 2.5mg and 5mg tablets remain available but cannot support increased demand.
- Alternative anticholinergic/non-anticholinergic agents for urinary incontinence remain available and can support increased demand (see supporting information).
A copy of this medicine supply notification, including supporting information, has been sent to all pharmacy NHS email addresses.
DHSC and NHS England have launched an online Medicines Supply Tool, which provides up-to-date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.
The Tool also details any changes to resupply dates and updates to the entries.
To access the Tool you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.
